Trials / NCT04068207
Minocycline Treatment in Retinitis Pigmentosa
Completed Phase 2 Drug / neuroprotection
- Sponsor
- Sun Yat-sen University
- Treatment
- Minocycline
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa, Inherited Retinal Dystrophy, Retina Disorder
- Ages
- 18 Years to 60 Years
- Enrollment
- 35 participants
- Started
- 2019-08-25
- Main results expected
- 2023-01-31
- Results posted
- Not yet
- Record last updated
- 2023-12-27
What the study is testing
The aim of this study is to evaluate the efficacy and safety of oral minocycline (100mg/d), administered for 6 months, for the treatment of patients with retinitis pigments(RP).
Where it runs
China (1)
- Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong